600196 复星医药
已收盘 09-30 15:00:00
资讯
新帖
简况
复星医药: 公司定期报告中主要按业务板块分部和重要子公司两个口径进行业绩披露
证星董秘互动 · 09-30 19:24
复星医药: 公司定期报告中主要按业务板块分部和重要子公司两个口径进行业绩披露
9月30日复星医药涨10.02%,招商国证生物医药指数(LOF)C基金重仓该股
证券之星 · 09-30 16:55
9月30日复星医药涨10.02%,招商国证生物医药指数(LOF)C基金重仓该股
9月30日复星医药涨停分析:疫苗,医疗器械,精准医疗概念热股
证券之星 · 09-30 16:34
9月30日复星医药涨停分析:疫苗,医疗器械,精准医疗概念热股
复星医药09月30日主力大幅流入2.06亿元 散户资金抛售
市场透视 · 09-30 15:17
复星医药09月30日主力大幅流入2.06亿元 散户资金抛售
复星医药(02196)上涨10.1%,报15.7元/股
金融界 · 09-30 13:45
复星医药(02196)上涨10.1%,报15.7元/股
异动快报:复星医药(600196)9月30日13点44分触及涨停板
证券之星 · 09-30 13:45
异动快报:复星医药(600196)9月30日13点44分触及涨停板
复星医药(02196.HK)子公司治疗结直肠癌药物获国家药监局批准上市
阿斯达克财经 · 09-30 09:27
复星医药(02196.HK)子公司治疗结直肠癌药物获国家药监局批准上市
复星医药(02196)控股子公司的奥沙利铂注射液上市注册申请获批准
智通财经 · 09-29 20:06
复星医药(02196)控股子公司的奥沙利铂注射液上市注册申请获批准
复星医药(02196.HK)子公司治疗恶性肿瘤创新药临床试验获批
阿斯达克财经 · 09-29 19:21
复星医药(02196.HK)子公司治疗恶性肿瘤创新药临床试验获批
复星医药(600196.SH)奥沙利铂注射液上市注册申请获批准
智通财经 · 09-29
复星医药(600196.SH)奥沙利铂注射液上市注册申请获批准
复星医药(02196):陈玉卿获选举为第九届董事会非执行董事
智通财经 · 09-27
复星医药(02196):陈玉卿获选举为第九届董事会非执行董事
复星医药(02196)拟为控股子公司复星医药产业提供担保
智通财经 · 09-27
复星医药(02196)拟为控股子公司复星医药产业提供担保
复星医药(600196.SH):XS-04片用于治疗血液系统恶性肿瘤临床试验获批
智通财经 · 09-27
复星医药(600196.SH):XS-04片用于治疗血液系统恶性肿瘤临床试验获批
复星医药09月27日主力资金流出120万元 连续3日减仓
市场透视 · 09-27
复星医药09月27日主力资金流出120万元 连续3日减仓
市场信心回暖,复星医药(600196.SH;02196.HK)AH股连日上涨领跑医药板块
智通财经 · 09-27
市场信心回暖,复星医药(600196.SH;02196.HK)AH股连日上涨领跑医药板块
复星医药自研创新药注射用青蒿琥酯援非抗疟入选福布斯ESG启发案例
证券之星 · 09-27
复星医药自研创新药注射用青蒿琥酯援非抗疟入选福布斯ESG启发案例
投资快报AI快讯:复星医药回购方案期限届满,共回购A股567.7万股
财富动力网 · 09-26
投资快报AI快讯:复星医药回购方案期限届满,共回购A股567.7万股
复星医药(02196)完成回购约567.77万股A股
智通财经 · 09-26
复星医药(02196)完成回购约567.77万股A股
复星医药(600196.SH)耗资1.27亿元完成回购A股567.77万股
智通财经网 · 09-26
复星医药(600196.SH)耗资1.27亿元完成回购A股567.77万股
复星医药:公司开展的多项国际多中心临床研究主要在中国、美国、澳大利亚、若干欧洲国家等国家和地区开展
每日经济新闻 · 09-26
复星医药:公司开展的多项国际多中心临床研究主要在中国、美国、澳大利亚、若干欧洲国家等国家和地区开展
暂无数据
公司概况
公司名称:
上海复星医药(集团)股份有限公司
所属行业:
医药制造业
上市日期:
1998-08-07
主营业务:
上海复星医药(集团)股份有限公司主营业务是制药、医疗器械、医学诊断、医疗健康服务。主要产品为心血管系统疾病治疗领域核心产品、中枢神经系统疾病治疗领域核心产品、血液系统疾病治疗领域核心产品、代谢及消化系统疾病治疗领域核心产品、抗感染疾病治疗领域核心产品、抗肿瘤治疗领域核心产品、原料药和中间体核心产品。根据中华人民共和国工信部中国医药工业信息中心颁布的2018年度中国医药工业百强企业榜单,本集团位列第7。由米内研究院主办的“中国医药工业百强系列榜单”,本集团成功入选“2022年度中国化药企业TOP100排行榜”,位列中国化药企业百强榜第6位;根据IQVIA统计,2023年第一季度本集团的医院用处方药销售收入位列全国第12位;根据全球医药智库信息平台InformaPharmaIntelligence发布的《2023年医药研发趋势年度分析》白皮书,本集团再次入选“全球医药企业研发管线规模Top25”。
发行价格:
7.15
{"stockData":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":27.67,"timestamp":1727679600000,"preClose":25.15,"halted":0,"volume":67474374,"delay":0,"floatShares":2118000000,"shares":2672000000,"eps":0.6862,"marketStatus":"已收盘","marketStatusCode":5,"change":2.52,"latestTime":"09-30 15:00:00","open":26.28,"high":27.67,"low":25.8,"amount":1821000000,"amplitude":0.0744,"askPrice":0,"askSize":0,"bidPrice":27.67,"bidSize":1705,"shortable":0,"etf":0,"ttmEps":0.6862,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1728351000000},"adr":0,"adjPreClose":25.15,"symbolType":"stock","openAndCloseTimeList":[[1727659800000,1727667000000],[1727672400000,1727679600000]],"highLimit":27.67,"lowLimit":22.63,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2672398711,"pbRate":1.57,"roa":"--","roe":"2.66%","epsLYR":0.89,"marketValue":73945000000,"floatMarketCap":58619000000,"peRate":40.32352,"changeRate":0.1002,"turnoverRate":0.0319,"status":0,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2024-10-08。"},"requestUrl":"/m/hq/s/600196/tweets","defaultTab":"tweets","newsList":[{"id":"2471806150","title":"复星医药: 公司定期报告中主要按业务板块分部和重要子公司两个口径进行业绩披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2471806150","media":"证星董秘互动","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471806150?lang=zh_cn&edition=full","pubTime":"2024-09-30 19:24","pubTimestamp":1727695452,"startTime":"0","endTime":"0","summary":"有关公司投资和出售资产情况,请以公司于法定渠道发布的公告信息为准。公司定期报告中主要按业务板块分部和重要子公司两个口径进行业绩披露。有关诊断板块的具体经营情况,可参见公司发布的定期报告。根据H股回购方案,本公司于2024年8月28日首次实施H股回购;截至2024年9月25日收市,本公司累计回购547.15股H股,累计回购总金额约为港币0.67亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409301927419f212a7a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409301927419f212a7a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0028","BK0060","BK0187","BK0188","BK0239","BK0096","600196","BK0175","BK0012","BK0183","BK0196"],"gpt_icon":0},{"id":"2471285875","title":"9月30日复星医药涨10.02%,招商国证生物医药指数(LOF)C基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2471285875","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471285875?lang=zh_cn&edition=full","pubTime":"2024-09-30 16:55","pubTimestamp":1727686531,"startTime":"0","endTime":"0","summary":"证券之星消息,9月30日复星医药涨10.02%创60日新高,收盘报27.67元,换手率3.19%,成交量67.47万手,成交额18.21亿元。根据2024基金半年报公募基金重仓股数据,重仓该股的公募基金共35家,其中持有数量最多的公募基金为招商国证生物医药指数C。招商国证生物医药指数C的前十大重仓股如下:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024093000028919.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","BK0028","BK0012","BK0183","02196","399441","BK0096","BK0187","BK0239","BK1593","BK0175","BK0060","BK1515","161726","BK0196","BK0188","600196"],"gpt_icon":0},{"id":"2471878716","title":"9月30日复星医药涨停分析:疫苗,医疗器械,精准医疗概念热股","url":"https://stock-news.laohu8.com/highlight/detail?id=2471878716","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471878716?lang=zh_cn&edition=full","pubTime":"2024-09-30 16:34","pubTimestamp":1727685293,"startTime":"0","endTime":"0","summary":"证券之星消息,复星医药9月30日涨停收盘,收盘价27.67元。该股于13点41分涨停,16次打开涨停,截止收盘封单资金为471.95万元,占其流通市值0.01%。9月30日的资金流向数据方面,主力资金净流入2.06亿元,占总成交额11.3%,游资资金净流出1.17亿元,占总成交额6.41%,散户资金净流出8919.1万元,占总成交额4.9%。近5日资金流向一览见下表:该股为疫苗,医疗器械,精准医疗概念热股,当日疫苗概念上涨12.92%,医疗器械概念上涨12.88%,精准医疗概念上涨12.35%。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024093000028042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK1515","159883","BK1191","BK1100","BK0196","BK0096","159646","BK0175","BK0188","BK0028","BK0012","BK0183","BK0060","BK1583","09997","BK1574","BK1593","BK1222","600196","02196","BK0239","09996"],"gpt_icon":0},{"id":"2471290688","title":"复星医药09月30日主力大幅流入2.06亿元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2471290688","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471290688?lang=zh_cn&edition=full","pubTime":"2024-09-30 15:17","pubTimestamp":1727680658,"startTime":"0","endTime":"0","summary":"09月30日, 复星医药股价涨10.02%,报收27.67元,成交金额18.21亿元,换手率3.19%,振幅7.44%,量比4.47。复星医药今日主力资金净流入2.06亿元,上一交易日主力净流出120万元。该股近5个交易日上涨23.80%,主力资金累计净流入1.92亿元;近20日主力资金累计净流入2.32亿元,其中净流入天数为8日。该行业中净流入前三个股分别为兴齐眼药、复星医药、艾力斯。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409301523499f20b59e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409301523499f20b59e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","BK0239","BK0060","BK0028","BK0196","BK0012","600196","BK0187","BK0175","BK0096","BK0183"],"gpt_icon":0},{"id":"2471847675","title":"复星医药(02196)上涨10.1%,报15.7元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2471847675","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471847675?lang=zh_cn&edition=full","pubTime":"2024-09-30 13:45","pubTimestamp":1727675135,"startTime":"0","endTime":"0","summary":"9月30日,复星医药(02196)盘中上涨10.1%,截至13:45,报15.7元/股,成交2.04亿元。上海复星医药是一家全球化医药健康产业集团,主要业务包括制药、医疗器械与医学诊断、医疗健康服务,并通过参股国药控股覆盖到医药商业领域。公司以患者为中心,通过自主研发、合作开发、许可引进、深度孵化的方式,持续丰富创新产品管线,提升新药的研究与临床开发能力,加快创新技术和产品的研发和转化落地。截至2024年中报,复星医药营业总收入203.83亿元、净利润12.25亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/09/30134543650617.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0175","BK0187","BK0196","BK1515","BK0096","BK0239","BK0028","BK1593","BK1191","BK0012","BK0183","BK0060","600196","02196","BK0188"],"gpt_icon":0},{"id":"2471847665","title":"异动快报:复星医药(600196)9月30日13点44分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2471847665","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471847665?lang=zh_cn&edition=full","pubTime":"2024-09-30 13:45","pubTimestamp":1727675130,"startTime":"0","endTime":"0","summary":"证券之星9月30日盘中消息,13点44分复星医药触及涨停板。目前价格27.67,上涨10.02%。该股为疫苗,医疗器械,精准医疗概念热股,当日疫苗概念上涨12.46%,医疗器械概念上涨12.01%,精准医疗概念上涨11.52%。近5日资金流向一览见下表:复星医药主要指标及行业内排名如下:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024093000019550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","BK0028","BK0012","BK0183","02196","BK0096","BK0187","BK0239","BK1593","BK0175","BK0060","BK1515","BK0196","BK0188","600196"],"gpt_icon":0},{"id":"2471818295","title":"复星医药(02196.HK)子公司治疗结直肠癌药物获国家药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2471818295","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471818295?lang=zh_cn&edition=full","pubTime":"2024-09-30 09:27","pubTimestamp":1727659620,"startTime":"0","endTime":"0","summary":"复星医药公布,控股子公司吉斯美(武汉)制药的奥沙利铂注射液上市注册申请,于近日获国家药品监督管理局批准。复星医药表示,截至今年8月,集团现阶段针对该新药累计研发投入约为352万元人民币。另外,去年已于中国境内获批上市的奥沙利铂注射剂,销售额约为22.97亿元人民币。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190604131519775_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190604131519775_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1384813/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0196","BK0012","BK1191","BK0096","BK0028","BK0239","BK1515","BK0188","BK0183","BK1593","02196","BK0175","BK0060","BK0187","600196"],"gpt_icon":0},{"id":"2471783772","title":"复星医药(02196)控股子公司的奥沙利铂注射液上市注册申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2471783772","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471783772?lang=zh_cn&edition=full","pubTime":"2024-09-29 20:06","pubTimestamp":1727611586,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复星医药 发布公告,该公司控股子公司吉斯美(武汉)制药有限公司的奥沙利铂注射液的上市注册申请于近日获国家药品监督管理局批准。该新药为集团自主研发的化学药品。截至2024年8月,集团现阶段针对该新药累计研发投入约为人民币352万元。该新药本次获批上市,可为相关肿瘤用药提供更多的选择,并进一步丰富集团产品剂型。预计该新药本次获批上市不会对集团现阶段业绩产生重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1188671.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","02196","BK1593","BK1191","BK0096","BK0060","BK0028","BK0188","BK1515","BK0012","BK0175","BK0183","BK0239","BK0187","600196"],"gpt_icon":0},{"id":"2471832857","title":"复星医药(02196.HK)子公司治疗恶性肿瘤创新药临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2471832857","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471832857?lang=zh_cn&edition=full","pubTime":"2024-09-29 19:21","pubTimestamp":1727608860,"startTime":"0","endTime":"0","summary":"复星医药(02196.HK) 公布,控股子公司星盛新辉收到国家药品监督管理局关于同意XS-04片用于治疗血液系统恶性肿瘤的临床试验批准。该新药为集团自主研发的小分子创新药,拟用于治疗血液系统恶性肿瘤,尤其是以弥漫性大B细胞淋巴瘤为主的B细胞淋巴瘤。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-09-27 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1384678/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1141","BK1191","BK0183","BK1161","600196","BK0239","BK1574","BK1576","BK0028","BK0188","BK0012","BK1515","BK0175","03347","BK0196","BK0060","BK0096","06978","BK0187","BK1593","BK1583","02196","159992"],"gpt_icon":0},{"id":"2471683558","title":"复星医药(600196.SH)奥沙利铂注射液上市注册申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2471683558","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471683558?lang=zh_cn&edition=full","pubTime":"2024-09-29 17:23","pubTimestamp":1727601828,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复星医药(600196.SH)公告,公司控股子公司吉斯美(武汉)制药有限公司的奥沙利铂注射液的上市注册申请于近日获国家药品监督管理局批准。公告显示,该新药主要用于与5-氟尿嘧啶和亚叶酸(甲酰四氢)联合应用于转移性结直肠癌的一线治疗、原发肿瘤完全切除后的III期(Duke’sC期)结肠癌的辅助治疗、以及不适合手术切除或局部治疗的局部晚期和转移的肝细胞癌(HCC)的治疗,与卡培他滨联合(XELOX)用于II期或III期胃腺癌患者根治切除术后的辅助化疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1188628.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02196","BK0060","BK1515","BK0012","BK0188","BK1593","BK0175","BK0096","BK0196","BK1191","600196","BK0183","BK0239","BK0028","BK0187"],"gpt_icon":0},{"id":"2470702988","title":"复星医药(02196):陈玉卿获选举为第九届董事会非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2470702988","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470702988?lang=zh_cn&edition=full","pubTime":"2024-09-27 20:03","pubTimestamp":1727438605,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复星医药(02196)发布公告,于临时股东大会上,陈玉卿获股东正式选举为第九届董事会非执行董事,委任自2024年9月27日起生效至本届董事会任期届满为止。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1188411.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","BK0096","BK0060","BK0188","BK0028","BK1515","BK0239","BK1593","BK0175","02196","BK0187","BK0196","BK0012","BK1191","600196"],"gpt_icon":0},{"id":"2470028677","title":"复星医药(02196)拟为控股子公司复星医药产业提供担保","url":"https://stock-news.laohu8.com/highlight/detail?id=2470028677","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470028677?lang=zh_cn&edition=full","pubTime":"2024-09-27 19:55","pubTimestamp":1727438108,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复星医药(02196)发布公告,该公司拟为控股子公司复星医药产业向招商银行申请的本金不超过等值人民币8.5亿元的授信额度项下债务提供最高额连带责任保证担保;控股子公司苏州二叶拟为其控股子公司山东二叶向莱商银行申请的本金不超过人民币1500万元的融资项下债务提供最高额连带责任保证担保。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1188406.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0175","BK0187","BK0196","BK1515","BK0096","BK0239","BK0028","BK1593","BK1191","BK0012","BK0183","BK0060","600196","02196","BK0188"],"gpt_icon":0},{"id":"2470870524","title":"复星医药(600196.SH):XS-04片用于治疗血液系统恶性肿瘤临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2470870524","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470870524?lang=zh_cn&edition=full","pubTime":"2024-09-27 18:46","pubTimestamp":1727433981,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复星医药(600196.SH)发布公告,公司控股子公司江苏星盛新辉医药有限公司(简称“星盛新辉”)于近日收到国家药品监督管理局关于同意XS-04片用于治疗血液系统恶性肿瘤的临床试验批准。星盛新辉拟于条件具备后于中国境内(不包括港澳台地区)开展该新药的I期临床试验。据悉,该新药为集团自主研发的小分子创新药,拟用于治疗血液系统恶性肿瘤,尤其是以弥漫性大B细胞淋巴瘤(DLBCL)为主的B细胞淋巴瘤。截至目前的临床前研究显示,该新药在多种血液肿瘤模型中展现出较为显著的抑制肿瘤生长的药效且安全性良好,有望解决既往BTK共价抑制剂治疗并产生耐药的问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1188306.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","BK1191","BK0183","600196","BK0239","BK1576","BK0028","BK0188","BK0012","BK1515","BK0175","03347","BK0196","BK0060","BK0096","BK0187","BK1593","BK1583","02196"],"gpt_icon":0},{"id":"2470204147","title":"复星医药09月27日主力资金流出120万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2470204147","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470204147?lang=zh_cn&edition=full","pubTime":"2024-09-27 15:17","pubTimestamp":1727421457,"startTime":"0","endTime":"0","summary":"09月27日, 复星医药股价涨5.01%,报收25.15元,成交金额6.52亿元,换手率1.24%,振幅3.97%,量比2.30。复星医药今日主力资金净流出120万元,连续3日净流出,上一交易日主力净流出2254万元,今日环比减少94.68%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为57.14%,平均跌幅为1.11%。该股近5个交易日上涨12.63%,主力资金累计净流出688万元;近20日主力资金累计净流入2412万元,其中净流入天数为7日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024092715233995812153&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024092715233995812153&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0028","BK0060","BK0187","BK0188","BK0239","BK0096","600196","BK0175","BK0012","BK0183","BK0196"],"gpt_icon":0},{"id":"2470074177","title":"市场信心回暖,复星医药(600196.SH;02196.HK)AH股连日上涨领跑医药板块","url":"https://stock-news.laohu8.com/highlight/detail?id=2470074177","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470074177?lang=zh_cn&edition=full","pubTime":"2024-09-27 12:03","pubTimestamp":1727409805,"startTime":"0","endTime":"0","summary":"医药板块中,国内医药龙头企业复星医药AH股均连日上扬,领跑板块。公告显示,截至2024年9月25日收市,A股回购方案实施期限届满,公司完成该方案的实施。其中,摩根士丹利将复星医药港股的目标价提升至17港元,并维持对复星医药的“增持”评级。中信证券给予复星医药A股32元的目标价,并维持“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1187995.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","BK0175","BK0196","600196","BK0239","BK0028","BK1593","BK0096","159938","BK0187","02196","BK0012","BK0183","BK1161","BK1515","BK0188","09939","BK1191","BK1574"],"gpt_icon":0},{"id":"2470716087","title":"复星医药自研创新药注射用青蒿琥酯援非抗疟入选福布斯ESG启发案例","url":"https://stock-news.laohu8.com/highlight/detail?id=2470716087","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470716087?lang=zh_cn&edition=full","pubTime":"2024-09-27 09:11","pubTimestamp":1727399501,"startTime":"0","endTime":"0","summary":"同时,复星医药凭借全球化的运营能力,积极将自主研发的青蒿素类创新产品带到非洲,为全球抗疟疾事业提供了中国的创新解决方案,发挥了ESG的包容、多元以及开放的特性,成功入选“ESG启发案例”,为企业ESG实践提供启发和借鉴。该案例获入选福布斯中国2024 ESG启发案例。2011年至今,复星医药自主研发生产的注射用青蒿琥酯Artesun一直是世界卫生组织推荐的儿童和成人重症疟疾治疗一线药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2024092700006378.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159717","02196","600196","BK0239","BK0175","BK0187","BK1515","BK0196","BK1593","BK1161","159992","BK0096","BK0012","BK0183","BK0060","BK0028","BK0188","06978","BK1574","BK1191"],"gpt_icon":0},{"id":"2470758336","title":"投资快报AI快讯:复星医药回购方案期限届满,共回购A股567.7万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2470758336","media":"财富动力网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470758336?lang=zh_cn&edition=full","pubTime":"2024-09-26 22:36","pubTimestamp":1727361401,"startTime":"0","endTime":"0","summary":"复星医药公告,截至2024年9月25日,公司A股回购方案期限届满,已回购A股5,677,700股,占公司总股本的0.21%,回购总金额约12,664.39万元人民币,回购价格区间为21.87元/股~23.52元/股。此次回购的A股拟用于员工持股计划或股权激励,若未能于三年内使用,将予以注销。同时,公司在同一期间还回购了H股5,471,500股,占公司总股本的0.20%,回购总金额约为港币6,689.59万元。股份结构变动表显示了回购前后的股份数量及比例变化。此次回购不会对公司经营、财务和未来发展产生重大影响,也不会导致公司控制权发生变化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240926223716957f923d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240926223716957f923d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02196","600196","BK1593","BK1515"],"gpt_icon":0},{"id":"2470784371","title":"复星医药(02196)完成回购约567.77万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2470784371","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470784371?lang=zh_cn&edition=full","pubTime":"2024-09-26 19:13","pubTimestamp":1727349190,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复星医药(02196)发布公告,截至2024年9月25日收市,A股回购方案实施期限届满,公司完成该方案的实施。于A股回购方案下,公司实际回购567.77万股A股(约占截至2024年9月25日公司总股本(即26.72亿股,下同)的0.21%),回购总金额约为人民币1.27亿元(不含交易费用),回购最高价人民币23.52元/股、最低价人民币21.87元/股、均价人民币22.31元/股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1187715.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","399300","BK0028","BK0188","BK0060","BK0012","BK0096","02196","BK1515","159982","BK0187","BK0175","BK1191","BK1593","BK0183","BK0196","600196"],"gpt_icon":0},{"id":"2470851617","title":"复星医药(600196.SH)耗资1.27亿元完成回购A股567.77万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2470851617","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470851617?lang=zh_cn&edition=full","pubTime":"2024-09-26 18:15","pubTimestamp":1727345730,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复星医药(600196.SH)发布公告,截至2024年9月25日收市,A股回购方案实施期限届满,公司完成该方案的实施。于A股回购方案下,公司实际回购567.77万股A股(约占截至2024年9月25日公司总股本的0.21%),回购总金额约为人民币1.27亿元(不含交易费用),回购最高价人民币23.52元/股、最低价人民币21.87元/股、均价人民币22.31元/股。更多港股重磅资讯,下载智通财经app更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1187645.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0028","BK0060","BK0096","BK0175","BK0183","399300","600196","BK0012","BK0187","BK0196","BK1191","BK0239","BK1515","02196","159982","BK1593","BK0188"],"gpt_icon":0},{"id":"2470204283","title":"复星医药:公司开展的多项国际多中心临床研究主要在中国、美国、澳大利亚、若干欧洲国家等国家和地区开展","url":"https://stock-news.laohu8.com/highlight/detail?id=2470204283","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470204283?lang=zh_cn&edition=full","pubTime":"2024-09-26 16:36","pubTimestamp":1727339785,"startTime":"0","endTime":"0","summary":"复星医药9月26日在投资者互动平台表示,截至目前,公司开展的多项国际多中心临床研究,主要在中国、美国、澳大利亚、若干欧洲国家等国家和地区开展。以斯鲁利单抗注射液为例,一项在广泛期小细胞肺癌患者中开展的国际多中心III期临床研究数据已用于支持斯鲁利单抗注射液于欧盟的上市许可申请,该申请已于2023年获欧洲药品管理局受理。有关公司主要在研品种的研发进展,请留意公司发布的临时公告和定期报告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240926163646957ee1f5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240926163646957ee1f5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0196","BK0096","BK0028","BK0060","BK0188","BK0012","BK0175","BK0183","BK0239","BK0187","600196"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1998-08-07","address":"上海市普陀区曹杨路510号9楼","stockEarnings":[{"period":"1week","weight":0.238},{"period":"1month","weight":0.2276},{"period":"3month","weight":0.2741},{"period":"6month","weight":0.1993},{"period":"1year","weight":-0.0213},{"period":"ytd","weight":0.1183}],"companyName":"上海复星医药(集团)股份有限公司","boardCode":"AI0027","perCapita":"--","boardName":"医药制造业","registeredCapital":"267132万元","compareEarnings":[{"period":"1week","weight":0.2138},{"period":"1month","weight":0.1739},{"period":"3month","weight":0.1133},{"period":"6month","weight":0.0871},{"period":"1year","weight":0.0727},{"period":"ytd","weight":0.1215}],"survey":" 上海复星医药(集团)股份有限公司主营业务是制药、医疗器械、医学诊断、医疗健康服务。主要产品为心血管系统疾病治疗领域核心产品、中枢神经系统疾病治疗领域核心产品、血液系统疾病治疗领域核心产品、代谢及消化系统疾病治疗领域核心产品、抗感染疾病治疗领域核心产品、抗肿瘤治疗领域核心产品、原料药和中间体核心产品。根据中华人民共和国工信部中国医药工业信息中心颁布的2018年度中国医药工业百强企业榜单,本集团位列第7。由米内研究院主办的“中国医药工业百强系列榜单”,本集团成功入选“2022年度中国化药企业TOP100排行榜”,位列中国化药企业百强榜第6位;根据IQVIA统计,2023年第一季度本集团的医院用处方药销售收入位列全国第12位;根据全球医药智库信息平台InformaPharmaIntelligence发布的《2023年医药研发趋势年度分析》白皮书,本集团再次入选“全球医药企业研发管线规模Top25”。","serverTime":1727865052220,"listedPrice":7.15,"stockholders":"0人","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(600196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(600196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,600196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(600196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(600196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}